We found that 93 protein-coding cancer genes carried probable driver ... understanding of the origins and consequences of somatic mutations in breast cancer. Figure 3: Extraction and contributions ...

Somatic mutations have been extensively characterized in breast cancer, but the effects of these genetic alterations on the proteomic landscape remain poorly understood. Here we describe ...

Oncotarget published "Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients" which reported that the association between genetic ...

Recent research and genomic studies have revealed a number of genes that accumulate somatic, or non-inherited, mutations and alterations in estrogen receptor positive (ER+) breast cancer.

mutation carriers with metastatic breast cancer (MBC). In addition, PARPi have demonstrated efficacy in patients with ovarian cancer with somatic BRCA1 or BRCA2 (sBRCA1/2) mutations. Other genes also ...

Breast cancer can run in families ... to cancer are acquired during your lifetime. These are called somatic mutations. Somatic mutations happen due to things like the natural aging process ...

BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

are a small subset of somatic mutations that drive the development of cancer. Dr Patrick Tarpey, first author from the Wellcome Trust Sanger Institute, said: “Breast cancer is the most common cancer ...

a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

“Our research study has demonstrated that poziotinib is highly potent in neratinib-resistant HER2 L755S lobular and ductal breast cancer models [...].” Somatic HER2 mutations are a novel class ...

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, "The uncharted role of HER2 mutant alleles in breast cancer." Somatic HER2 mutations are a novel class ...